Arcutis Biotherapeutics Inc
Research Arcutis Biotherapeutics Inc (ARQT) on Bullrun: valuation model: 57.7% overvalued, market cap USD 3.34B, P/E 128.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARQT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal57.7% overvalued
- Market capUSD 3.34B
- P/E128.3
- Financial periodQ2 2026
- RevenueUSD 129.86M
- Net incomeUSD 15.01M
- Free cash flowUSD 12.48M
- Gross margin91.6%
Valuation Snapshot
Bullrun's latest valuation model marks Arcutis Biotherapeutics Inc as 57.7% overvalued; latest market cap is USD 3.34B; P/E is 128.3.
Peer valuation comparison
Latest P/E is 128.34x versus a Healthcare sector median of 24.64x (420.9% above).
Latest P/E is 128.34x versus a United States median of 23.85x (438.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 376.07M | -USD 16.14M | -USD 6.31M | 90.2% | -0.13 | USD 42.91M | USD 108.96M | USD 189.48M |
| FY2024 | USD 196.54M | -USD 140.04M | -USD 112.30M | 90.3% | -1.16 | USD 71.34M | USD 107.20M | USD 157.54M |
| FY2023 | USD 59.61M | -USD 262.14M | -USD 247.49M | 91.6% | -3.78 | USD 88.40M | USD 201.80M | USD 88.67M |
| FY2022 | USD 3.69M | -USD 311.46M | -USD 258.05M | 79.5% | -5.66 | USD 53.64M | USD 197.77M | USD 209.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 3.34B | 128.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.58B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.64B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 304.85M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 901.73M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.04B | n/a | n/a | n/a |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Arcutis Biotherapeutics Inc overvalued or undervalued?
Bullrun's valuation model currently marks Arcutis Biotherapeutics Inc as 57.7% overvalued.
What is Arcutis Biotherapeutics Inc's market cap?
Arcutis Biotherapeutics Inc's market capitalization is USD 3.34B.
What is Arcutis Biotherapeutics Inc's P/E ratio?
Arcutis Biotherapeutics Inc's price-to-earnings (P/E) ratio is 128.3.
What does Arcutis Biotherapeutics Inc do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.